Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARa Agonists as Leads for Retinal Disorders.
Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARa Agonists as Leads for Retinal Disorders. J Med Chem. 2020 03 26; 63(6):2854-2876.